Press "Enter" to skip to content

WHO halts hydroxychloroquine, HIV drugs in COVID trials after failure to reduce death

South Sudan NEWS PORTAL (JUBA CITY)

A bottle and pills of Hydroxychloroquine sit on a counter at Rock Canyon Pharmacy in Provo, Utah, on May 20, 2020. (Photo by GEORGE FREY / AFP) (Photo by GEORGE FREY/AFP via Getty Images)

The World Health Organization (WHO) said on Saturday that it was discontinuing its trials of the malaria drug hydroxychloroquine and combination HIV drug lopinavir/ritonavir in hospitalised patients with COVID-19 after they failed to reduce mortality.

The setback came as the WHO also reported more than 200,000 new cases globally of the disease for the first time in a single day. The United States accounted for 53,213 of the total 212,326 new cases recorded on Friday, the WHO said.

“These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalised COVID-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect,” the WHO said in a statement, referring to large multicountry trials that the agency is leading.

S.Sudan NEWS PORTAL:  Gogrial police assure residents of safety during New Year celebration

The U.N. agency said the decision, taken on the recommendation of the trial’s international steering committee, does not affect other studies where those drugs are used for non-hospitalised patients or as a prophylaxis.

Another branch of the WHO-led trial is looking at the potential effect of Gilead’s antiviral drug remdesivir on COVID-19. The European Commission on Friday gave remdesivir conditional approval for use after being shown to shorten hospital recovery times.

The solidarity trial started out with five branches looking at possible treatment approaches to COVID-19: standard care; remdesivir; hydroxychloroquine; lopinavir/ritonavir; and lopanivir/ritonavir combined with interferon.

WHO director-general Tedros Adhanom Ghebreyesus told reporters on Friday that nearly 5,500 patients in 39 countries had been recruited so far into its clinical trials and that interim results were expected within two weeks.

S.Sudan NEWS PORTAL:  Two South African routes included in ‘most scenic drives in the world’ list

Some 18 experimental COVID-19 vaccines are being tested on humans among nearly 150 treatments under development.

Mike Ryan, WHO’s top emergencies expert, said on Friday that it would be unwise to predict when a vaccine could be ready. While a vaccine candidate might show its effectiveness by year’s end, the question was how soon it could then be mass-produced, he said.

Continue reading at Africa Live – CGTN Africa

As reported by Africa Live – CGTN Africa. Enjoyed this news story? Read more South Sudan news features on Africa Live – CGTN Africa.

Credits : Africa Live – CGTN Africa (https://africa.cgtn.com) → Author : South Sudan PRESS REVIEW

Publishing and Aggregation by : South Sudan NEWS PORTAL

S.Sudan NEWS PORTAL:  Bullen Chol bags Best Photographer of the Year Award

Permission : Central Press Syndicate South Sudan

Facebook : South Sudan NEWS PORTAL

We respect the intellectual property rights of our news sources and expect our users to do the same. We may provide links to external news sources from time to time, but any trademarks, logos, photographs and videos remain their copyrighted works. If you feel our website violates fair use or infringes on your copyright, inform us immediately for redress.

The Central Press Syndicate of South Sudan publishes articles related to South Sudan from press wires, verified social media sources and Google news, thereby centralizing South Sudanese news from all over the web, in an easy to read format.

Read related stories with similar tags below:

Be First to Comment

Leave a Reply